MYRTLE BEACH, SC and QUEBEC CITY, Aug. 29, 2018 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has appointed Mr. Martin J. Madden to the Company's board of directors.
Mr. Madden has a broad background in medical device innovation and new product development. Mr. Madden spent thirty years with Johnson & Johnson's Medical Device organization, and, as an executive and a vice-president of Johnson & Johnson, Martin served on the management boards of Johnson & Johnson's Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, and was also Chairman of Johnson & Johnson's Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Martin's leadership experiences spanned internal start-ups, executing turn-around's, and leading large portfolio and technology intensive research organizations.
"We are pleased to add Martin to our team," stated R.M. (Ric) Rumble, president and CEO of TSO3. "His experience in medical device technology and commercialization is sure to benefit us as we move forward with our commercial objectives."TE
Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company's website at www.tso3.com.
SOURCE TSO3 Inc.
For further information: Company Contacts: R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, Email: email@example.com; Glen Kayll, CFO, Tel: 418 651-0003, Email: firstname.lastname@example.org; Investor Relations: Gilmartin Group, Greg Chodaczek, Tel: 610-368-6505, Email: Greg@gilmartinir.com; Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, Email: email@example.com